Archives | LinksMedicus Free Medical News & Perspectives

Solidarity is key to protect the world from pandemics. This call by over 30 governments for a #PandemicTreaty to prepare for & respond to pandemics shows collaboration at work. The upcoming #WHASpecial session is a historic opportunity to make the world safer. https://t.co/98TgPce03t

— Tedros Adhanom Ghebreyesus (@DrTedros) November 23, 2021

Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA.

24 Nov, 2021 | 08:47h | UTC

Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA – The Lancet

Cohort study found the risk of myocardial infarction may be best predicted by the number of apolipoprotein B containing lipoproteins.

24 Nov, 2021 | 08:41h | UTC

Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content – JAMA Cardiology (link to abstract – $ for full-text)

Commentaries:

ApoB Gains Ground as Best Lipid Predictor of MI Risk – TCTMD

Study finds risk of MI best captured by number of apolipoprotein B lipoproteins – MedicalResearch

Commentary on Twitter

Study from @marstonMD @TIMIStudyGroup et al found lipid-associated risk for myocardial infarction is best captured by the number of apoB-containing lipoproteins, independent from lipid content (cholesterol or TG) or type of lipoprotein (LDL or TG-rich) https://t.co/UBby6mtj6e

— JAMA Cardiology (@JAMACardio) November 13, 2021

Review: COVID-19-associated Invasive Fungal Infection.

24 Nov, 2021 | 08:48h | UTC

COVID-19-associated Invasive Fungal Infection – Open Forum Infectious Diseases

Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis.

M-A: Incidence and mortality of COVID‐19‐associated pulmonary aspergillosis – The incidence and mortality in the ICU were estimated to be 10.2% and 54.9%, respectively.

Consensus Guideline: Defining and managing COVID-19-associated pulmonary aspergillosis

Bacterial and fungal superinfections in critically ill patients with COVID-19

Invasive Fungal Disease complicating COVID-19: when it rains it pours

A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU

Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients

Commentary on Twitter

A new article in OFID reviews COVID-19-associated fungal infections and addresses gaps in knowledge relating to the epidemiology, diagnosis and management of these infections: https://t.co/JIkkW70zHI #IDSAJournals #OpenForumInfectDis @PaulSaxMD @DrJLi @jobadd @DrPappasID pic.twitter.com/bPmFdKkjmb

— IDSA (@IDSAInfo) November 21, 2021

AGA Clinical practice update on management of chronic gastrointestinal pain in disorders of gut–brain interaction.

24 Nov, 2021 | 08:42h | UTC

AGA Clinical Practice Update on Management of Chronic Gastrointestinal Pain in Disorders of Gut–Brain Interaction: Expert Review – Clinical Gastroenterology and Hepatology

Viewpoint: The growing phenomenon of “virtual-first” primary care.

24 Nov, 2021 | 08:39h | UTC

The Growing Phenomenon of “Virtual-First” Primary Care – JAMA (free for a limited period)

We expected people with asthma to fare worse during COVID. Turns out they’ve had a break.

24 Nov, 2021 | 08:44h | UTC

We expected people with asthma to fare worse during COVID. Turns out they’ve had a break – The Conversation

Safety analysis of RCTs showed Alzheimer’s drug Aducanumab caused brain swelling in 35% of patients, and 26.0% experienced associated symptoms (e.g., headache, confusion, dizziness, and nausea).

24 Nov, 2021 | 08:35h | UTC

Commentary: Biogen Alzheimer’s drug shows brain swelling in 35% of patients – MedicalXpress

Commentary on Twitter

Amyloid-related imaging abnormalities occurred in ~ 40% of participants in the phase 3 studies of aducanumab. Approximately one-quarter of patients with amyloid-related imaging abnormalities experience symptoms https://t.co/TnUPXT686l

— JAMA Neurology (@JAMANeuro) November 22, 2021

Three Neurologic Societies, Including the AAN, Issue Strong Position Statement on Aducanumab.

24 Nov, 2021 | 08:36h | UTC

Three Neurologic Societies, Including the AAN, Issue Strong Position Statement on Aducanumab – Neurology Today

See statement: Decisions With Patients and Families Regarding Aducanumab in Alzheimer Disease, With Recommendations for Consent: AAN Position Statement – Neurology

Editorial: Aducanumab for Alzheimer’s disease?

FDA approvement of Alzheimer’s drug sparks controversy among doctors.

Commentary on Twitter

Decisions With Patients and Families Regarding #Aducanumab in Alzheimer Disease, With Recommendations for Consent—Read the full AAN @AANMember Position Statement: https://t.co/ckoIVRi4DE #Neurology pic.twitter.com/q8TSU67zm9

— Neurology Journal (@GreenJournal) November 19, 2021

Systematic Review: Renal denervation may have a modest effect in improving 24h ambulatory blood pressure monitoring (reduction in SBP by 5.29 mmHg and DBP by 3.75 mmHg) but does not improve major cardiovascular outcomes and renal function.

24 Nov, 2021 | 08:33h | UTC

Summary: Renal denervation for improving outcomes in individuals with resistant hypertension – Cochrane Library

Original Review: Renal denervation for resistant hypertension – Cochrane Library

Commentary on Twitter

https://twitter.com/CochraneHTN/status/1462979551558995971

Chest Pain: Who needs additional testing beyond ECG and Troponin?

24 Nov, 2021 | 08:28h | UTC

Chest Pain: Who Needs Additional Testing Beyond ECG and Troponin? – JACC: Case Reports

RCT: A brief 5:2 diet advice resulted in similar weight loss at one year vs. a standard multicomponent weight-management advice (-2.6kg vs. -1.9kg, p = 0.37).

24 Nov, 2021 | 08:29h | UTC

A randomised controlled trial of the 5:2 diet – PLOS One

News Release: Brief 5:2 diet advice is as effective as traditional GP advice, but people like it better, according to new study – Queen Mary University of London

Commentary: Fasting 2 days a week can help obese people keep off the weight with modest results, study finds – CNN

A prospective cohort study showed a 3.1% risk for recurrent venous thromboembolism at 90 days in patients with subsegmental pulmonary embolism managed without anticoagulation.

24 Nov, 2021 | 08:31h | UTC

Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation: A Multicenter Prospective Cohort Study – Annals of Internal Medicine (link to abstract – $ for full-text)

Commentary on Twitter

First prospective study including patients with isolated SSPE managed without anticoagulation published in @AnnalsofIM. Rate of recurrent VTE is 3.1% . Nice collaboration between @INNOVTE1 and @canvector funded by @HeartandStroke https://t.co/GdcbM1fRp1 @OttMethodsCentr

— Marc Carrier (@MarcCarrier1) November 23, 2021

Review: A Road Map of the Axial Spondyloarthritis Continuum.

24 Nov, 2021 | 08:27h | UTC

A Road Map of the Axial Spondyloarthritis Continuum – Mayo Clinic Proceedings

Opinion: Texting thumb, trigger finger, gamer’s thumb and other smartphone injuries.

24 Nov, 2021 | 08:24h | UTC

Texting Thumb, Trigger Finger, Gamer’s Thumb and Other Smartphone Injuries – Scientific American

Review: Prevention and treatment of atrial fibrillation via risk factor modification.

24 Nov, 2021 | 08:25h | UTC

Prevention and Treatment of Atrial Fibrillation via Risk Factor Modification – American Journal of Cardiology

Systematic Review: Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.

24 Nov, 2021 | 08:22h | UTC

Summary: Selective serotonin reuptake inhibitors for stroke recovery – Cochrane Library

Original Article: Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery – Cochrane Library

RCT: Routine treatment with fluoxetine does not reduce the incidence of depression after stroke.

[Abstract Only] Randomized trial: Fluoxetine does not improve functional recovery after acute stroke

Randomized Trial: Effects of Fluoxetine on Functional Outcomes After Acute Stroke

Commentary on Twitter

Selective #serotonin reuptake inhibitors for #stroke recovery https://t.co/7R5bijz49e Updated @CochraneStroke systematic review: 'reduced risk of future depression by about a quarter, but led to a slight increase in the risk of seizures & increased the risk of bone fractures.'

— The Cochrane Library (@CochraneLibrary) November 19, 2021

[Preprint] Systematic Review: Duration of Effectiveness of Vaccines Against SARS-CoV-2 Infection and COVID-19 Disease – “effectiveness against COVID-19 severe disease remained high (>70%) in most studies in the six months after full vaccination, although it did decrease some (on average, 8-10 percentage points) between one and six months after full vaccination”.

23 Nov, 2021 | 08:57h | UTC

Duration of Effectiveness of Vaccines Against SARS-CoV-2 Infection and COVID-19 Disease: Results of a Systematic Review and Meta-Regression – Preprints with The Lancet – SSRN

Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine.

China’s COVID vaccines have been crucial — now immunity is waning.

[Preprint] Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – “Vaccine protection declined by mid-August 2021, decreasing from 91.9% in March to 53.9%”.

Observational study in Qatar showed the effectiveness of Pfizer vaccine against any SARS-CoV-2 infection dropped to 20% in months 5 through 7 after the second dose, but effectiveness against severe Covid-19 remained high.

Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.

Editorial | Covid-19 vaccination: evidence of waning immunity is overstated.

COVID vaccine immunity is waning — how much does that matter? – “As debates about booster shots heat up, what’s known about the duration of vaccine-based immunity is still evolving”.

COVID vaccine effects wane over time but still prevent death and severe illness.

Perspective | What we actually know about waning immunity.

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

Systematic Review: Vaccines for preventing rotavirus diarrhea.

24 Nov, 2021 | 08:20h | UTC

Vaccines for preventing rotavirus diarrhoea: vaccines in use – Cochrane Library

Summary: Are rotavirus vaccines safe and effective in preventing rotavirus diarrhoea in infants and children? – Cochrane Library

Commentary: Vaccines for preventing rotavirus diarrhoea: an updated Cochrane review – Cochrane Library

Optimal dose of aripiprazole for augmentation therapy of antidepressant-refractory depression: preliminary findings based on a systematic review and dose–effect meta-analysis.

24 Nov, 2021 | 08:23h | UTC

Optimal dose of aripiprazole for augmentation therapy of antidepressant-refractory depression: preliminary findings based on a systematic review and dose–effect meta-analysis – The British Journal of Psychiatry

Commentary on Twitter

Low-doses of aripiprazole [2-5 mg] as augmentation treatment for depression might achieve the optimal balance between efficacy, tolerability and acceptability, per this meta-analysis (certainty of evidence low to moderate)https://t.co/aTkcQOsORp

— Awais Aftab (@awaisaftab) November 21, 2021